Gross Margin: A company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage. Calculated as: Gross Income / Total Revenues
Sorrento Therapeutics, Inc. (SRNE) had Gross Margin of 46.77% for the most recently reported fiscal year, ending 2022-12-31.
| Income Statement Financials | |
$62.84M |
|
$-572.84M |
|
$33.45M |
|
$29.39M |
|
$567.15M |
|
$-504.31M |
|
$-57.43M |
|
$-561.75M |
|
$-561.75M |
|
$-559.33M |
|
$-577.76M |
|
$-577.76M |
|
$-559.33M |
|
$-504.31M |
|
$-484.28M |
|
419.31M |
|
419.31M |
|
$-1.37 |
|
$-1.37 |
|
| Balance Sheet Financials | |
$96.37M |
|
$51.97M |
|
$376.47M |
|
$472.84M |
|
$327.92M |
|
$19.13M |
|
$166.59M |
|
$494.51M |
|
$-21.67M |
|
$-238.84M |
|
$-21.67M |
|
522.82M |
|
| Cash Flow Statement Financials | |
$-293.86M |
|
$-28.52M |
|
$311.72M |
|
$36.66M |
|
$23.63M |
|
$-13.03M |
|
$74.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.29 |
|
-- |
|
-- |
|
-7.53 |
|
-1.63 |
|
|
Gross Margin |
46.77% |
-802.55% |
|
-802.55% |
|
-770.66% |
|
-893.95% |
|
-911.60% |
|
$-307.51M |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
3.35 |
|
2.57 |
|
142.13 |
|
2666.29% |
|
241.90% |
|
-122.19% |
|
22755.29% |
|
$-0.04 |
|
$-0.73 |
|
$-0.70 |
|